MKI67 and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss: Figure 3E,F represents the quantification results of immune staining for Ki-67. No significant differences in Ki-67 immune staining were observed in SBS patients without teduglutide compared to healthy controls (Figure 3E). In contrast, Ki-67-positive immune staining increased when SBS patients were treated with teduglutide (Figure 3F).